Caplin Steriles (Caplin), a Subsidiary Company of Caplin Point Laboratories has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Difluprednate Ophthalmic Emulsion, 0.05% (Eye drops), a generic therapeutic equivalent version of the Reference Listed Drug (RLD) DUREZOL, from Sandoz Inc.Powered by Capital Market - Live News

Net profit of Caplin Point Laboratories rose 13.87% to Rs 130.80 crore in the quarter ended September 2024 as against Rs 114.87 crore during the previous quarter ended September 2023. Sales rose 17.81% to Rs 483.10 crore in the quarter ended September 2024 as against Rs 410.06 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales483.10410.06 18 OPM %34.0833.51 - PBDT185.22157.76 17 PBT168.46146.00 15 NP130.80114.87 14 Powered by Capital Market - Live News

Caplin Point Laboratories will hold a meeting of the Board of Directors of the Company on 7 November 2024Powered by Capital Market - Live News

Caplin Point Laboratories announced that the 33th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live News

Caplin Point Laboratories announced that the Board of Directors of the Company at its meeting held on 7 August 2024, inter alia, have recommended the final dividend of Rs 2.5 per equity Share (i.e. 125%) , subject to the approval of the shareholders.Powered by Capital Market - Live News